INEOS Industries Holdings Limited

Annual report and financial statements Registered number 6958119 31 December 2016

THURSDAY

A686CIDK

A18 08/06/2017 COMPANIES HOUSE

Contents

| | Page |
|--|------|
| Strategic Report | 3 |
| Directors' Report | 4 |
| Independent auditors' report to the members of INEOS Industries Holdings Limited | 6 |
| Profit and Loss Account | 8 |
| Balance Sheet | 9 |
| Statement of Changes in Equity | 10 |
| Notes (forming part of the financial statements) | 11 |

Strategic Report

The directors present their strategic report for the year ended 31 December 2016.

Principal activities and business review

The principal activity of the Company is the management activities of a financial holding company.

Future developments

The Company held its investments in the year and will continue to do for the foreseeable future.

Principal risks and uncertainties

The principal risk and uncertainty of the business is the potential impairment of the investments it holds. The directors review the investments for impairment annually or when an indication of impairment is deemed to exist.

Exceptional item

The Company has recognised €27.3 million of exceptional administrative expenses in the year. These expenses include an impairment of a bond indenture held with INEOS New Planet BioEnergy LLC, a subsidiary undertaking, of €8.8 million as the recoverability of this debtor is considered doubtful. In addition a loan balance of €18.5 million with INEOS Bio Limited, a subsidiary undertaking, has been written off during the year, as this entity is being dissolved and the loan is no longer recoverable.

Key performance indicators ("KPIs")

Given the straightforward nature of the business, the Company's directors are of the opinion that analysis using KPIs is not necessary for an understanding of the development, performance or position of the business.

Results

The result for the year ended 31 December 2016 was a profit for the financial year of ϵ 1,120,916,000 (2015: loss ϵ 38,567,000).

Dividends

A dividend of €22,982,000 was declared and paid during the year (2015: €10,844,000).

Approved and signed on behalf of the board

G Leask Director

5 June 2017

Directors' Report

The directors present their report and the audited financial statements for the year ended 31 December 2016.

Directors

The directors who held office during the year and up to the date of signing the financial statements are given below: J F Ginns G Leask

Financial risk management

The company's operations expose it to a variety of financial risks that include the effects of changes in credit risk, liquidity risk and interest rate risk. The company has in place a risk management programme that seeks to limit the adverse effects on the financial performance of the company where appropriate. The company is funded internally by the INEOS group and therefore has no direct exposure to liquidity or debt market risk. Interest rate exposures are managed on a group basis.

Statement of directors' responsibilities

The directors are responsible for preparing the Annual report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 "Reduced Disclosure Framework", and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 101, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' Report (continued)

Disclosure of information to auditors

The directors confirm that as far as they are aware, there is no relevant audit information of which the Company's auditors are unaware and that they have taken all steps necessary as directors in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Independent auditors

PricewaterhouseCoopers LLP are deemed to be reappointed in accordance with an elective resolution made under section 487 of the Companies Act 2006.

Approved and signed on behalf of the Board

G Leask Director

INEOS Industries Holdings Limited

Hawkslease, Chapel Lane, Lyndhurst, SO43 7FG

5 June 2017

Independent auditors' report to the members of INEOS Industries Holdings Limited

Report on the financial statements

Our opinion

In our opinion, INEOS Industries Holdings Limited's financial statements (the "financial statements"):

- give a true and fair view of the state of the company's affairs as at 31 December 2016 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
 and
- have been prepared in accordance with the requirements of the Companies Act 2006.

What we have audited

The financial statements, included within the Annual report and financial statements (the "Annual report"), comprise:

- the Balance Sheet as at 31 December 2016;
- the Profit and Loss Account for the year then ended;
- the Statement of Changes in Equity for the year then ended; and
- the notes to the financial statements, which include a summary of significant accounting policies and other explanatory information.

The financial reporting framework that has been applied in the preparation of the financial statements is United Kingdom Accounting Standards, comprising FRS 101 "Reduced Disclosure Framework", and applicable law (United Kingdom Generally Accepted Accounting Practice).

In applying the financial reporting framework, the directors have made a number of subjective judgements, for example in respect of significant accounting estimates. In making such estimates, they have made assumptions and considered future events.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Strategic report and the Directors' report. We have nothing to report in this respect.

Other matters on which we are required to report by exception

Adequacy of accounting records and information and explanations received

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not received all the information and explanations we require for our audit; or
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Independent auditors' report to the members of INEOS Industries Holdings Limited (continued)

Directors' remuneration

Under the Companies Act 2006 we are required to report to you if, in our opinion, certain disclosures of directors' remuneration specified by law are not made. We have no exceptions to report arising from this responsibility.

Responsibilities for the financial statements and the audit

Our responsibilities and those of the directors

As explained more fully in the Statement of directors' responsibilities set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland) ("ISAs (UK & Ireland)"). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

What an audit of financial statements involves

We conducted our audit in accordance with ISAs (UK & Ireland). An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of:

- whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed;
- the reasonableness of significant accounting estimates made by the directors; and
- the overall presentation of the financial statements.

We primarily focus our work in these areas by assessing the directors' judgements against available evidence, forming our own judgements, and evaluating the disclosures in the financial statements.

We test and examine information, using sampling and other auditing techniques, to the extent we consider necessary to provide a reasonable basis for us to draw conclusions. We obtain audit evidence through testing the effectiveness of controls, substantive procedures or a combination of both.

In addition, we read all the financial and non-financial information in the Annual report and financial statements to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report. With respect to the Strategic report and Directors' report, we consider whether those reports include the disclosures required by applicable legal requirements.

Ian Marsden (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Newcastle upon Tyne
5 June 2017

Profit and Loss Account for the year ended 31 December 2016

| | Note | | |
|---|------|-------------|----------|
| | | 2016 | 2015 |
| | | €000 | €000 |
| Revenue | | 150 | - |
| Gross profit | | 150 | |
| Gross profit | | , | |
| Administrative expenses | | (353) | (155) |
| Exceptional administrative expenses | 3 | (27,342) | (87,410) |
| Total administrative expenses | | (27,695) | (87,565) |
| Operating loss | | (27,545) | (87,565) |
| Income from shares in group undertakings | 5 | 1,156,306 | 56,812 |
| Income from other fixed asset investments | | 179 | - |
| Profit/(loss) on disposal of investment | 6 | 1,982 | (2,176) |
| Interest receivable and similar income | 7 | 55,802 | 22,413 |
| Interest payable and similar expenses | 8 | (65,808) | (28,226) |
| Profit/(loss) before taxation | | 1,120,916 | (38,742) |
| Tax on profit/(loss) | 9 | - | 175 |
| Profit/(loss) for the financial year | | 1,120,916 | (38,567) |
| | | | |

All activities of the company relate to continuing operations.

The company has no recognised other comprehensive income and therefore no separate statement of comprehensive income has been presented.

Balance Sheet As at 31 December 2016

| | Note | | | | |
|---|------|-------------|--------------|--------------|--------------|
| | | 2016 | 2016 €000 | 2015 €000 | 2015 €000 |
| Fixed assets | | €000 | €000 | 6000 | 6000 |
| Investments | 10 | | 1,150,460 | | 285,003 |
| Other investments | 11 | | 7,100 | | 7,100 |
| Other financial assets | 12 | | 4,000 | | 4,000 |
| Current assets | | | 1,161,560 | | 296,103 |
| Debtors (including €776,093,000 (2015: | 13 | 942,133 | 1,101,000 | 878,851 | |
| €710,822,000) due after more than one year Cash at bank and in hand | | 42.200 | | 5.000 | |
| Cash at bank and in hand | | 43,208 | | 5,969 | |
| | | 985,341 | | 884,820 | |
| Creditors: amounts falling due within one year | 14 | (53,215) | | (327,361) | |
| Net current assets | | | 932,126 | <u></u> | 557,459 |
| | | | | | 052.562 |
| Total assets less current liabilities | | | 2,093,686 | | 853,562 |
| Creditors: amounts falling due after more than one year | 15 | | (992,297) | | (850,107) |
| | | | | | |
| Net assets | | | 1,101,389 | | 3,455 |
| | | | | | |
| Capital and reserves | | | | | |
| Called up share capital | 16 | | - | | - |
| Profit and loss account | | | 1,101,389 | | 3,455 |
| Total shareholders' funds | | | 1,101,389 | | 3,455 |
| | | | | | |

These financial statements on pages 8 to 22 were approved by the board of directors on 5 June 2017 and were signed on its behalf by:

G Leask
Director

Company registered number: 6958119

Statement of Changes in Equity for the year ended 31 December 2016

| | Called up Share capital | Profit and loss account | Total shareholders' funds |
|-----------------------------|-------------------------------|-------------------------|---------------------------------|
| | €000 | €000 | €000 |
| Balance at 1 January 2015 | - | 52,866 | 52,866 |
| Loss for the financial year | | (38,567) | (38,567) |
| Dividends (note 17) | - | (10,844) | (10,844) |
| Balance at 31 December 2015 | _ | 3,455 | 3,455 |

| | Called up Share capital | Profit and loss account | Total shareholders' funds |
|-------------------------------|-------------------------------|-------------------------|---------------------------------|
| | €000 | €000 | €000 |
| Balance at 1 January 2016 | - | 3,455 | 3,455 |
| Profit for the financial year | - | 1,120,916 | 1,120,916 |
| Dividends (note 17) | • | (22,982) | (22,982) |
| Balance at 31 December 2016 | | 1,101,389 | 1,101,389 |

Notes (forming part of the financial statements)

1 Accounting policies

INEOS Industries Holdings Limited (the "Company") is a private company, limited by shares, incorporated and registered in England.

The Company is exempt by virtue of section 400 of the Companies Act 2006 from the requirement to prepare group financial statements. These financial statements present information about the Company as an individual undertaking and not about its group.

These financial statements were prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101").

In preparing these financial statements, the Company applies the recognition, measurement and disclosure requirements of International Financial Reporting Standards as adopted by the EU ("Adopted IFRSs"), but makes amendments where necessary in order to comply with Companies Act 2006 and has set out below where advantage of the FRS 101 disclosure exemptions has been taken.

INEOS Industries Limited is the parent undertaking of the only group of undertakings to consolidate these financial statements. The consolidated financial statements of INEOS Industries Limited are prepared in accordance with International Financial Reporting Standards and may be obtained from Company Secretary, Hawkslease, Chapel Lane, Lyndhurst, Hampshire, SO43 7FG.

In these financial statements, the company has applied the exemptions available under FRS 101 in respect of the following disclosures:

- a Cash Flow Statement and related notes;
- Disclosures in respect of transactions with wholly owned subsidiaries;
- · Disclosures in respect of capital management;
- The effects of new but not yet effective IFRSs;
- Disclosures in respect of the compensation of Key Management Personnel.

As the consolidated financial statements of INEOS Industries Limited include the equivalent disclosures, the Company has also taken the exemptions under FRS 101 available in respect of the following disclosures:

- IFRS 2 Share Based Payments in respect of group settled share based payments;
- Certain disclosures required by IAS 36 Impairment of assets in respect of the impairment of goodwill and indefinite life intangible assets;
- Disclosures required by IFRS 5 Non-current Assets Held for Sale and Discontinued Operations in respect of the cash flows of discontinued operations;
- Certain disclosures required by IFRS 13 Fair Value Measurement and the disclosures required by IFRS 7 Financial Instrument Disclosure.

The accounting policies set out below have, unless otherwise stated, been applied consistently on the going concern basis, to all periods presented in these financial statements and in accordance with the Companies Act 2006 as applicable to companies using FRS 101.

1 Accounting policies (continued)

1.1 Measurement convention

The financial statements are prepared on the historical cost basis.

1.2 Going concern

The financial statements are prepared on a going concern basis under the historical cost convention, except that the following assets and liabilities which are stated at their fair value: derivative financial instruments, financial instruments classified as fair value through the profit or loss or as available-for-sale, in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom. Based on the budgeted cash flows of the Company and its subsidiaries and taking into account the facilities available, the directors continue to adopt the going concern basis in preparing the financial statements.

1.3 Foreign currency

Transactions in foreign currencies are translated to the Company's functional currencies at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are retranslated to the functional currency at foreign exchange rates ruling at the dates the fair value was determined. Foreign exchange differences arising on translation are recognised in the profit and loss account.

1.4 Non-derivative financial instruments

Non-derivative financial instruments comprise investments in equity and debt securities, trade and other debtors, cash and cash equivalents, loans and borrowings, and trade and other creditors.

Trade and other debtors

Trade and other debtors are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses.

Trade and other creditors

Trade and other creditors are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method.

Investments in jointly controlled entities, associates and subsidiaries are carried at cost less impairment.

Interest-bearing borrowings

Interest-bearing borrowings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, interest-bearing borrowings are stated at amortised cost using the effective interest method, less any impairment losses.

1.5 Provisions

A provision is recognised in the balance sheet when the Company has a present legal or constructive obligation as a result of a past event, that can be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects risks specific to the liability.

1 Accounting policies (continued)

1.6 Taxation

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the profit and loss account except to the extent that it relates to items recognised directly in equity or other comprehensive income, in which case it is recognised directly in equity or other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised.

1.7 Investments in subsidiaries

Investments are stated in the balance sheet at cost less any provisions for impairment.

1.8 Interest

Interest income and interest payable is recognised in profit or loss as it accrues, using the effective interest method. Foreign currency gains and losses are reported on a net basis.

1.9 Critical judgements and estimates in applying the accounting policies

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the application of the accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

There are no significant estimates and judgements that are considered to relate to the Company. Estimates and underlying assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are reasonable under the circumstances.

1.10 Exceptional items

The presentation of the Company's results separately identifies the effect of profits and losses on the disposal of businesses, the impairment and the reversal of impairment of non-current assets, the cost of restructuring acquired businesses and the impact of one off events such as legal settlements as exceptional items. Results excluding disposals, impairments, restructuring costs and one off items are used by management and are presented in order to provide readers with a clear and consistent presentation of the underlying operating.

2 Auditors' remuneration

The audit fee has been included in the overall audit fee for INEOS Industries Limited both in the current and prior year and is not separately recharged to the company.

3 Exceptional administrative expenses

The Company has recognised ϵ 27.3 million of exceptional administrative expenses in the year. These expenses include an impairment of a bond indenture held with INEOS New Planet BioEnergy LLC, a subsidiary undertaking, of ϵ 8.8 million as the recoverability of this debtor is considered doubtful. In addition a loan balance of ϵ 18.5 million with INEOS Bio Limited, a subsidiary undertaking, has been written off during the year, as this entity is being dissolved and the loan is no longer recoverable.

In 2015, the company recognised €87.4 million of exceptional administrative expenses. These expenses represent €90.4 million write off of a debtor balance with INEOS Bio SA, a related party, partially offset by exceptional administrative income of €3.0 million in relation to the acquisition of the Styrolution joint venture.

4 Staff numbers and costs

The company had no employees during the year (2015: nil).

No directors received any fees or remuneration in respect of their services to the company during the financial year (2015: none).

5 Income from shares in group undertakings

During the year the company received income from shares in group undertakings comprising dividend income from INEOS Styrolution Investment GmbH (€972.5 million), INEOS Styrolution Holding Limited (€174.6 million), INEOS Melamines Germany GmbH (€7.4 million) and INEOS ChloroToluenes Limited (€1.8 million). In 2015 the company received dividend income from INEOS Melamines Germany GmbH (€5.5 million) and Grangemouth CHP Limited (€51.3 million).

6 Profit/(loss) on disposal of investment

In the year the company disposed of investments relating to the sale of the Ineos Styrenics business to Synthos S.A, a Polish company for €56.5 million, resulting in a profit on disposal of €2.0 million.

7 Interest receivable and similar income

| | 2016 €000 | 2015 €000 |
|--|--------------|--------------|
| Interest receivable and similar income | 55,802 | 17,486 |
| Exchange gains | - | 4,927 |
| • | | |
| Total other interest receivable and similar income | 55,802 | 22,413 |
| | | |

Interest receivable and similar income includes €55,802,000 (2015: €17,486,000) receivable from group undertakings.

8 Interest payable and similar expenses

| | 2016 €000 | 2015 €000 |
|---|--------------|--------------|
| Interest payable and similar expenses | 59,766 | 28,226 |
| Exchange losses | 6,042 | - |
| Total other interest payable and similar expenses | 65,808 | 28,226 |

Interest payable and similar charges includes €59,766,000 (2015: €28,226,000) payable to group undertakings.

9 Tax on profit/(loss)

| Recognised in the profit and loss account | **** | 2015 |
|--|----------------------|------------------|
| | 2016 €000 | 2015 €000 |
| | €000 | 6000 |
| UK Corporation tax | - | 175 |
| | | |
| | | |
| | | |
| Reconciliation of effective tax rate | | |
| | 2016 | 2015 |
| | €000 | €000 |
| Tax on profit/(loss) | | 175 |
| talt on proto (toss) | | |
| Profit/(loss) before taxation | 1,120,916 | (38,742) |
| D. C.//1> 1/- 1/11 | 224 102 | (7.945) |
| Profit/(loss) multiplied by the standard rate of tax in the UK of 20% (2015: 20.25%) Expenses (income not taxable)/ not deductible | 224,183 (226,225) | (7,845) 6,651 |
| Group relief not paid | 2,042 | - |
| Tax losses (utilisation of losses not previously recognised)/ not recognised | • | 1,194 |
| Over/ under provided in previous years | - | (175) |
| | | |
| Tax on profit/(loss) | - | (175) |
| | | |

Changes to the UK corporation tax rates were substantively enacted as part of Finance Bill 2015 (on 26 October 2015) and Finance Bill 2016 (on 7 September 2016). These include reductions to the main rate to 19% from 1 April 2017 and to 17% from 1 April 2020.

10 Investments

| | Subsidiaries |
|--|--------------------------------|
| Cost | €000 |
| At beginning of year Additions Disposal (note 6) | 285,003 919,974 (54,517) |
| At end of year | 1,150,460 |

During the year the company had additions of &6919,974,000 to increase the carrying value of its Styrolution investment, following a restructure of the business. The company also disposed of investments of &654,517,000 relating to the sale of the INEOS Styrenics business during the year (see note 6).

The directors believe the carrying value of the investments is supported by the underlying net assets of the subsidiaries.

| Country of Shares Country of Net | | | Class of | Ownership | |
|--|--|--------------------------|-----------------------|-----------|------|
| INEOS Industries America I LLC(2) United States Ordinary 100% 100% INEOS Industries America II LLC(3) United States Ordinary 100% 100% INEOS ABS (USA) LLC*(4) United States Ordinary 100% 100% INEOS Mexico S de RL de CV(5) Mexico Ordinary 100% 100% INEOS Bio USA LLC(6) United States Ordinary 100% 80% INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% 80% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 80% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Esources Limited(13) UK Ordinary 100% 80% INEOS Calabrian Holdings Corporation (15) United States< | Investments in subsidiaries | Country of incorporation | shares <u>held</u> | 2016 | 2015 |
| INEOS Industries America II LLC(3) United States Ordinary 100% INEOS ABS (USA) LLC*(4) United States Ordinary 100% INEOS Mexico S de RL de CV(5) Mexico Ordinary 100% INEOS Bio USA LLC(6) United States Ordinary 100% INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 100% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 100% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Resources Limited(13) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 80% INEOS Calabrian Holdings Corporation(17) United States Ordinary 100% 0% | Grangemouth CHP Limited*(1) | UK | Ordinary | 100% | 100% |
| INEOS ABS (USA) LLC*(4) United States Ordinary 100% INEOS Mexico S de RL de CV(5) Mexico Ordinary 100% INEOS Bio USA LLC(6) United States Ordinary 100% INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% 80% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS Bio Holdings Limited*(11) UK Ordinary 100% 80% INEOS Bio Elimited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 80% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 10% | INEOS Industries America I LLC(2) | United States | Ordinary | 100% | 100% |
| INEOS Mexico S de RL de CV(5) Mexico Ordinary 100% INEOS Bio USA LLC(6) United States Ordinary 100% INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% 80% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 80% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Eximited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 10% <td>INEOS Industries America II LLC(3)</td> <td>United States</td> <td>Ordinary</td> <td>100%</td> <td>100%</td> | INEOS Industries America II LLC(3) | United States | Ordinary | 100% | 100% |
| INEOS Bio USA LLC(6) United States Ordinary 100% 80% INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% 80% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 80% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Limited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 0% INEOS ChloroToluenes Belgium NV(19) Belgium Ordinar | INEOS ABS (USA) LLC*(4) | United States | Ordinary | 100% | 100% |
| INEOS New Planet BioEnergy LLC(7) United States Ordinary 100% 80% INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 80% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Limited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 9% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS Calabrian Corporation(17) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 100% INEOS Meastricht BV(20) Netherlands Ord | INEOS Mexico S de RL de CV(5) | Mexico | Ordinary | 100% | 100% |
| INEOS Enterprises US Newco LLC(8) United States Ordinary 100% 0% INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 80% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Esources Limited(13) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS Calabrian Corporation(17) United States Ordinary 100% 0% INEOS Chloro Toluenes Elimited(18) UK Ordinary 100% 100% INEOS Maastricht BV(20) Netherlands Ordinary 100% 100% INEOS Healthcare Holdings Limited(21) UK Ordinary 100% 100% INEOS Melamines GmbH(23) Germany <td< td=""><td>INEOS Bio USA LLC(6)</td><td>United States</td><td>Ordinary</td><td>100%</td><td>100%</td></td<> | INEOS Bio USA LLC(6) | United States | Ordinary | 100% | 100% |
| INEOS Melamines LLC(9) United States Ordinary 100% 100% INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 100% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Limited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS Calabrian Corporation(17) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 100% INEOS Maastricht BV(20) Netherlands Ordinary 100% 100% INEOS Healthcare Holdings Limited(21) UK Ordinary 100% 100% INEOS Healthcare Limited(22) UK Ordinary | INEOS New Planet BioEnergy LLC(7) | United States | Ordinary | 100% | 80% |
| INEOS Styrenics US LLC(10) United States Ordinary 100% 100% INEOS ABS (UK) Limited*(11) UK Ordinary 100% 100% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Limited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS Calabrian Corporation(17) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 100% INEOS Maastricht BV(20) Netherlands Ordinary 100% 100% INEOS Healthcare Holdings Limited(21) UK Ordinary 100% 100% INEOS Healthcare Limited(22) UK Ordinary 100% 100% INEOS Melamines GmbH(23) Germany Ordinary | INEOS Enterprises US Newco LLC(8) | United States | Ordinary | 100% | 0% |
| INEOS ABS (UK) Limited*(11) UK Ordinary 100% 100% INEOS Bio Holdings Limited*(12) UK Ordinary 100% 80% INEOS Bio Limited(13) UK Ordinary 100% 80% INEOS Bio Resources Limited(14) UK Ordinary 100% 80% INEOS Calabrian Corporation Canada inc(15) Canada Ordinary 100% 0% INEOS Calabrian Holdings Corporation(16) United States Ordinary 100% 0% INEOS Calabrian Corporation(17) United States Ordinary 100% 0% INEOS ChloroToluenes Limited(18) UK Ordinary 100% 100% INEOS ChloroToluenes Belgium NV(19) Belgium Ordinary 100% 100% INEOS Maastricht BV(20) Netherlands Ordinary 100% 100% INEOS Healthcare Holdings Limited(21) UK Ordinary 100% 100% INEOS Melamines GmbH(23) Germany Ordinary 100% 100% INEOS Melamines Pte Ltd(24) Singapore Ordinary | INEOS Melamines LLC(9) | United States | Ordinary | 100% | 100% |
| INEOS Bio Holdings Limited*(12) INEOS Bio Limited(13) INEOS Bio Limited(13) INEOS Bio Resources Limited(14) INEOS Bio Resources Limited(14) INEOS Calabrian Corporation Canada inc(15) INEOS Calabrian Holdings Corporation(16) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary IO0% INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) INEOS Styrenics UK Limited(25) INEOS Melamines Melamine | INEOS Styrenics US LLC(10) | United States | Ordinary | 100% | 100% |
| INEOS Bio Limited(13) INEOS Bio Resources Limited(14) INEOS Bio Resources Limited(14) INEOS Calabrian Corporation Canada inc(15) INEOS Calabrian Holdings Corporation(16) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary INEOS Melamines Grid Ino% INEOS Melamines Inom Inom INEOS Melamines Inom INEOS Melami | INEOS ABS (UK) Limited*(11) | UK | Ordinary | 100% | 100% |
| INEOS Bio Resources Limited(14) INEOS Calabrian Corporation Canada inc(15) INEOS Calabrian Holdings Corporation(16) INEOS Calabrian Holdings Corporation(17) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS Calabrian Corporation(17) INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary IO0% INEOS Melamines Ordinary IO0% INEOS Melamines Ordinary IO0% INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary IO0% INEOS Melamines INEOS Styrenics UK Limited(25) INEOS Melamines INEOS M | INEOS Bio Holdings Limited*(12) | UK | Ordinary | 100% | 80% |
| INEOS Calabrian Corporation Canada inc(15)CanadaOrdinary100%0%INEOS Calabrian Holdings Corporation(16)United StatesOrdinary100%0%INEOS Calabrian Corporation(17)United StatesOrdinary100%100%INEOS ChloroToluenes Limited(18)UKOrdinary100%100%INEOS ChloroToluenes Belgium NV(19)BelgiumOrdinary100%100%INEOS Maastricht BV(20)NetherlandsOrdinary100%100%INEOS Healthcare Holdings Limited(21)UKOrdinary100%100%INEOS Healthcare Limited(22)UKOrdinary100%100%INEOS Melamines GmbH(23)GermanyOrdinary100%100%INEOS Melamines Pte Ltd(24)SingaporeOrdinary100%100%INEOS Styrenics UK Limited(25)UKOrdinary100%100% | INEOS Bio Limited(13) | UK | Ordinary | 100% | 80% |
| INEOS Calabrian Holdings Corporation(16) INEOS Calabrian Corporation(17) INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) United States Ordinary 100% 0% UNITED States Ordinary 100% 100% 100% 100% 100% INEOS Melamines OmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% | INEOS Bio Resources Limited(14) | UK | Ordinary | 100% | 80% |
| INEOS Calabrian Corporation(17) INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) United States Ordinary 100% | INEOS Calabrian Corporation Canada inc(15) | Canada | Ordinary | 100% | 0% |
| INEOS ChloroToluenes Limited(18) INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary IO0% IO0% IO0% IO0% IO0% IO0% IO0% INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary IO0% | INEOS Calabrian Holdings Corporation(16) | United States | Ordinary | 100% | 0% |
| INEOS ChloroToluenes Belgium NV(19) INEOS Maastricht BV(20) INEOS Healthcare Holdings Limited(21) INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) Belgium Ordinary 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% | INEOS Calabrian Corporation(17) | United States | Ordinary | 100% | 0% |
| INEOS Maastricht BV(20)NetherlandsOrdinary100%100%INEOS Healthcare Holdings Limited(21)UKOrdinary100%100%INEOS Healthcare Limited(22)UKOrdinary100%100%INEOS Melamines GmbH(23)GermanyOrdinary100%100%INEOS Melamines Pte Ltd(24)SingaporeOrdinary100%100%INEOS Styrenics UK Limited(25)UKOrdinary100%100% | INEOS ChloroToluenes Limited(18) | UK | Ordinary | 100% | 100% |
| INEOS Healthcare Holdings Limited(21)UKOrdinary100%100%INEOS Healthcare Limited(22)UKOrdinary100%100%INEOS Melamines GmbH(23)GermanyOrdinary100%100%INEOS Melamines Pte Ltd(24)SingaporeOrdinary100%100%INEOS Styrenics UK Limited(25)UKOrdinary100%100% | INEOS ChloroToluenes Belgium NV(19) | Belgium | Ordinary | 100% | 100% |
| INEOS Healthcare Limited(22) INEOS Melamines GmbH(23) INEOS Melamines Pte Ltd(24) INEOS Styrenics UK Limited(25) UK Ordinary 100% 100% 100% 100% 100% 100% | INEOS Maastricht BV(20) | Netherlands | Ordinary | 100% | 100% |
| INEOS Melamines GmbH(23)GermanyOrdinary100%INEOS Melamines Pte Ltd(24)SingaporeOrdinary100%INEOS Styrenics UK Limited(25)UKOrdinary100% | INEOS Healthcare Holdings Limited(21) | UK | Ordinary | 100% | 100% |
| INEOS Melamines Pte Ltd(24)SingaporeOrdinary100%INEOS Styrenics UK Limited(25)UKOrdinary100% | INEOS Healthcare Limited(22) | UK | Ordinary | 100% | 100% |
| INEOS Styrenics UK Limited(25) UK Ordinary 100% | INEOS Melamines GmbH(23) | Germany | Ordinary | 100% | 100% |
| • | INEOS Melamines Pte Ltd(24) | Singapore | Ordinary | 100% | 100% |
| INEOS Styrenics International S.A*(26) Switzerland Ordinary 100% 100% | INEOS Styrenics UK Limited(25) | UK | Ordinary | 100% | 100% |
| | INEOS Styrenics International S.A*(26) | Switzerland | Ordinary | 100% | 100% |

10 Investments (continued)

| | Country of | Class of shares | Owner | ship |
|--|---------------|-----------------|-------|--------|
| Investments in subsidiaries | incorporation | held | 2016 | 2015 |
| DIFOC Services Condition | C | 0-4: | 1000/ | 10007 |
| INEOS Styrenics GmbH(27) | Germany | Ordinary | 100% | 100% |
| INEOS Styrenics Manufacturing GmbH(28) | Germany | Ordinary | 100% | 100% |
| INEOS Styrenics Germany GmbH(29) | Germany | Ordinary | 100% | 100% |
| INEOS Vinyls Holdings Italia S.r.l.*(30) | Italy | Ordinary | 100% | 100% |
| INEOS Films Italia S.r.l(31) | Italy | Ordinary | 100% | 100% |
| INEOS Styrolution Holding Limited(32) | UK | Ordinary | 100% | 100% |
| INEOS Styrolution Financing Limited(33) | UK | Ordinary | 100% | 100% |
| INEOS Styrolution Investment GmbH(34) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Holding GmbH(35) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Beteiligungs GmbH(36) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Group GmbH(37) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Belgium N.V.(38) | Belgium | Ordinary | 100% | 100% |
| INEOS Styrolution Belgium Service bvta(39) | Belgium | Ordinary | 100% | 100% |
| INEOS Styrolution Brazil Holding B.V.(40) | Brazil | Ordinary | 100% | 100% |
| Styrolution do Brasil ABS S.A(41) | Brazil | Ordinary | 100% | 99.92% |
| INEOS Styrolution (Thailand) Co., Ltd.(42) | Thailand | Ordinary | 100% | 100% |
| INEOS Styrolution do Brasil Polimeros Ltda(43) | Brazil | Ordinary | 100% | 100% |
| INEOS Styrolution France S.A.S(44) | France | Ordinary | 100% | 100% |
| INEOS Styrolution France Services S.A.S(45) | France | Ordinary | 100% | 100% |
| INEOS Styrolution Europe GmbH(46) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Schwarzheide GmbH(47) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Koln GmbH(48) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Ludwigshafen GmbH(49) | Germany | Ordinary | 100% | 100% |
| INEOS Styrolution Verwaltungs GmbH(50) | Germany | Ordinary | 100% | 100% |
| Styrolution India Private Limited(51) | India | Ordinary | 75% | 75% |
| INEOS Styrolution India Ltd(52) | India | Ordinary | 100% | 100% |
| INEOS Styrolution Iberia, S.L(53) | Spain | Ordinary | 100% | 100% |
| INEOS Styrolution OOO(54) | Russia | Ordinary | 100% | 100% |
| INEOS Styrolution America LLC(55) | United States | Ordinary | 100% | 100% |
| INEOS Styrolution Canada Limited(56) | Canada | Ordinary | 100% | 100% |
| INEOS Styrolution Switzerland S.A(57) | Switzerland | Ordinary | 100% | 100% |
| INEOS Styrolution Italia S.r.1(58) | Italy | Ordinary | 100% | 100% |
| INEOS Styrolution Kimyasal Urunler Ticaret Limited(59) | Turkey | Ordinary | 100% | 100% |
| INEOS Styrolution Korea Ltd(60) | Korea | Ordinary | 100% | 100% |
| INEOS Styrolution Mexicana S.A. de C.V(61) | Mexico | Ordinary | 100% | 100% |
| INEOS Styrolution Netherlands B.V(62) | Netherlands | Ordinary | 100% | 100% |
| INEOS Styrolution Poland z.o.o(63) | Poland | Ordinary | 100% | 100% |
| INEOS Styrolution Servicios S.A. de C.V.(64) | Mexico | Ordinary | 100% | 100% |
| INEOS Styrolution APAC Pte. Ltd(65) | Singapore | Ordinary | 100% | 100% |
| INEOS Strolution Hong Kong Co Limited(66) | Hong Kong | Ordinary | 100% | 100% |
| INEOS Styrolution Polymers (Shanghai) Co Limited(67) | China | Ordinary | 100% | 100% |

10 Investments (continued)

| | Country of | | Ownership | |
|--|--------------------------|-----------------------|-----------|------|
| Investments in subsidiaries | Country of incorporation | shares <u>held</u> | 2016 | 2015 |
| INEOS Styrolution Polymers (Shanghai) Co Limited - | China | Ordinary | 100% | 100% |
| Guangzhou Branch (68) | | | | |
| INEOS Styrolution Vietnam Co Ltd(69) | Vietnam | Ordinary | 100% | 100% |
| INEOS Styrolution UK Limited(70) | UK | Ordinary | 100% | 100% |
| INEOS Styrolution US Holding LLC(71) | United States | Ordinary | 100% | 100% |
| INEOS Upstream Limited(72) | UK | Ordinary | 100% | 100% |
| INEOS Upstream Services Limited(73) | UK | Ordinary | 100% | 100% |
| INEOS UK E&P Holding Limited(74) | UK | Ordinary | 100% | 100% |
| INEOS Offshore BCS Limited(75) | UK | Ordinary | 100% | 100% |
| INEOS Clipper South B Limited(76) | UK | Ordinary | 100% | 100% |
| INEOS Clipper South C Limited(77) | UK | Ordinary | 100% | 100% |
| INEOS UK SNS Limited(80) | UK | Ordinary | 100% | 100% |
| INEOS 120 Energy Limited(81) | UK | Ordinary | 100% | 0% |
| INEOS 120 Exploration Limited(82) | UK | Ordinary | 100% | 0% |
| INEOS 120 Power Limited(83) | UK | Ordinary | 100% | 0% |
| INEOS Industries Property Limited(84) | UK | Ordinary | 100% | 100% |
| INEOS Styrolution APAC Pte. Ltd - Japan Branch(85) | Japan | Ordinary | 100% | 100% |

^{*}held directly by the Company as at 31 December 2016

The registered office addresses of the investments disclosed in this note are:

| Reference | Registered office address |
|--|---|
| (1) | Utilities Control Building, East Office, PO Box 30, Bo'Ness Road, |
| (0.0.4.0.16.15.55.51) | Grangemouth, FK3 9XQ, United Kingdom |
| (2,3,4,8,16,17,55,71) | Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, United |
| (5) | States Camino del Lago #4740, Colonia Cortijo del Rio, Monterrey Nuevo, Leon, |
| (5) | Mexico |
| (6,10) | 2600 South Shore Boulevard, League City, TX 77573, United States |
| (7) | 3030 Warrenville Road suite 160, Lisle, IL 60532, United States |
| (9) | 730B Worcester Street, Springfield MD, MA 01151, United States |
| (11,12,13,14,21,22,32,33,72,73,76,81,82,83,84) | |
| (15) | Suite 6000, 100 King Street West, Toronto ON MSX 1E2, Canada |
| (18,25) | Runcorn Site HQ, South Parade, PO Box 9, Runcorn, Cheshire, WA7 4JE, |
| | United Kingdom |
| (19) | Heilig Hartlaan 21, 3980 Tessenderlo, Belgium |
| (20) | Ankerkade 111, 6222 NI Maastricht, The Netherlands |
| (23) | Alt Fechenheim 34, 60386 Frankfurt am Main, Germany |
| (24) | Boardroom Corporate & Advisory Service Pte Ltd, 50 Raffles Place, #32-01 |
| 40 6 970 | Singapore Land Tower, Singapore, 048623 Singapore |
| (26,57) | 3 Avenue des Uttins, 1180 Rolle, Vaud, Switzerland |
| (27,28,29) | Paul Baumann Strasse 1, D-45764, Marl, Germany |
| (30,31) | Via XXIV Maggio 1, 21043 Castiglione Olona, Varese, Italy |
| (34,35,36,37,46,49,50) | Mainzer Landstrasse 50, 60325 Frankfurt, Germany |
| (38) | Haven 725, Scheldelaan 600, 2040 Antwerp, Belgium |

| Reference | Registered office address |
|--|--|
| (39) | 2070 Zwijndrecht, Nieuwe Weg 1, 1053 Haven, Mechelen, Belgium |
| (40,62) | Strawinskylaan 411, NL - 1077 Amsterdam, The Netherlands |
| (41,43) | Rua Arandu 57, anterior 1544 conjuntos 11 and 12, Brooklin Paulista, Sao Paulo 04562-910, |
| | Brazil |
| (42) | No 4/2 1-8 Road, T. Map Ta Phut, A Muang, 2115 Rayong, Thailand |
| (44) | Rue Albert Duplat, F-62410, Wingles, France |
| (45) | 95 rue la Boetie, F-75008, Paris, France |
| (47) | Schipkauer Strasse 1, 01987 Schwarzheide, Germany |
| (48) | Alte Strasse 201, 50769 Cologne, Germany |
| (51) | Mumbai, India |
| (52) | 6th Floor, ABS Towers, Old Padra Road, 39007 Vadodara, India |
| (53) | Ronda General Mitre 28-30, 08017 Barcelona, Spain |
| (56) | 872 Tashmoo Avenue, Sarnia ON N7T 8A3 Ontario, Canada |
| (58) | Via Caldera 21, 20153 Milano Cesano Maderno, Italy |
| (59) | Buyukdere Cad. Meydan Sok., Spring Giz Plaza K. 13 N 11, Maslak Sariyer, Istanbul, Turk |
| (60) | Sanggae-ro 143, (Sanggae-dong), Nam-gu, Ulsan, South Korea |
| (61,64) | Avenida Insurgentes Sur No. 863, Piso 6, Colonia Napoles, 03810, Mexico City, Mexico Ul. Wooloska 9, 02-583 Warszawa Legionowo, Poland |
| (63) | 111 Somerset Road, #08 238164 Singapore, Singapore |
| (65) (66) | Room 816, 8/F, Miramar Tower, 132 Nathan Road, Tsimshatsui, Hong Kong, China |
| (66) (67) | Suite 2304, Central Towers, 567 Langao Road, Putuo District, Shanghai 200333, China |
| (67) (68) | Suite 3406, Teem Tower, No. 208, Tianhe Road, Tianhe District, Guangzhou 510620, |
| (08) | Shanghai, China |
| (69) | 11 th Floor, Lotte Center Hanoi, 54 Lieu Giai Street, Hanoi, Vietnam |
| (70) | c/o DWF LLP, 1 Scott Place, 2 Hardman Street, Manchester M3 3AA, United Kingdom |
| (74) | |
| | Brodies House 31 – 33 Union Grove, Aberdeen, AB10 6SD, United Kingdom |
| | Brodies House 31 – 33 Union Grove, Aberdeen, AB10 6SD, United Kingdom 4th Floor, 90 High Holborn, London WCIV 9LJ, United Kingdom |
| (75,77,80) | Brodies House 31 – 33 Union Grove, Aberdeen, AB10 6SD, United Kingdom 4 th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan |
| (75,77,80) (85) | 4th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom |
| (75,77,80) (85) | 4 th Floor, 90 High Holborn, London WCIV 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 |
| (75,77,80) (85) | 4 th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan |
| (75,77,80) (85) | 4 th Floor, 90 High Holborn, London WCIV 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 €000 €000 7,100 11,100 |
| (75,77,80) (85) I Other investments At 1 January | 4 th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 €000 €000 |
| (75,77,80) (85) 11 Other investments At 1 January Reclassification | 4 th Floor, 90 High Holborn, London WCIV 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 €000 €000 7,100 11,100 |
| (75,77,80) (85) I Other investments At 1 January Reclassification | 4 th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 €000 €000 7,100 11,100 - (4,000) |
| (75,77,80) (85) 11 Other investments At 1 January Reclassification | 4 th Floor, 90 High Holborn, London WC1V 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 €000 €000 7,100 11,100 - (4,000) - (4,000) - 7,100 7,100 - (0,000) - (0 |
| (75,77,80) (85) | 4 th Floor, 90 High Holborn, London WCIV 9LJ, United Kingdom Nishishinjuku 1-25-1, Shinjuku-ku, Tokyo-to, Japan 2016 2015 6000 6000 7,100 11,100 - (4,000) 7,100 7,100 |

The registered address of Fluxel SAS is Route Gay Lussac, BP43, 13117, Lavera, France.

Fluxel S.A.S....

France

20%

20%

12 Other financial assets

| | 016 2015 000 €000 |
|---------------------------|------------------------------------|
| Other financial assets 4, | 4,000 |

Available for sale financial assets

Available for sale financial assets relate to a 5.43% investment in Access Technologies plc, a company registered in the UK whose principal activity is the development, commercialization and licensing of technology for the manufacture of Accoya wood, Tricoya wood elements and related acetylation technologies. The amount is shown at historic cost.

13 Debtors

| | 2016 €000 | 2015 €000 |
|--|---------------|----------------|
| Amounts owed by group undertakings Other debtors | 942,043 90 | 878,723 128 |
| | 942,133 | 878,851 |
| Due within one year | 166,040 | 168,029 |
| Due after more than one year | 776,093 | 710,822 |

Amounts owed by group undertakings are unsecured, attract interest at commercial rates and are either subject to standard trading terms or are repayable on demand.

14 Creditors: amounts falling due within one year

| | 2016 | 2015 |
|------------------------------------|--------|---------|
| | €000 | €000 |
| Amounts owed to group undertakings | 20,418 | 296,936 |
| Amounts owed to related parties | 32,797 | 30,392 |
| Other creditors | - | 33 |
| | | |
| | 53,215 | 327,361 |
| | | |

Amounts owed to group undertakings are unsecured, attract interest at commercial rates and are either subject to standard trading terms or are repayable on demand.

15 Creditors: amounts falling after more than one year

| | 2016 €000 | 2015 €000 |
|--|--------------------|-------------------|
| Amounts owed to group undertakings Amounts owed to related parties | 173,975 818,322 | 10,022 840,085 |
| | 992,297 | 850,107 |
| | | |

Amounts owed to group undertakings are unsecured, attract interest at commercial rates and are repayable in 2-5 years.

16 Called up share capital

| | 2016 | 2015 |
|--|------|------|
| | €000 | €000 |
| Allotted, called up and fully paid | | |
| 2 (2015: 2) ordinary shares of £1.00 each | • | |
| 214,913 (2015: 214,913) business tracker shares of 0.001p each | • | - |
| | | |

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company.

As the reporting currency of the Company is the Euro, share capital has been converted to Euros at the effective rate of exchange ruling at the date of issuance.

A summary of the rights that attach to each class of shares is as follows:

The holders of the Business Tracker shares shall be entitled to receive dividends as determined by the Company out of profits of the Company available for distribution in a financial year up to a maximum of 10% of such profits available for distribution or such higher amount as the Special Committee may determine. On a return of capital, the holders of the Business Tracker shares shall be entitled to receive up to a maximum of 10% of the surplus assets of the Company remaining after the payment of its liabilities, or such higher amount as the Special Committee may determine. Each holder of Business Tracker shares shall receive that portion of the surplus assets for the year over which the Business Tracker shares have been held by them. The holders of the Business Tracker shares are not entitled to vote at any general meeting of the Company.

The holders of the Ordinary shares shall be entitled to receive dividends as determined by the Company out of the profits remaining after the deduction of the proportion of the profits attributed to the holders of the relevant Business Tracker shares. On a return of capital, the holders of the Ordinary shares shall be entitled to receive that portion of the surplus assets remaining after the deduction of the proportion of the surplus assets attributed to the holders of the relevant Business Tracker shares. The holders of the Ordinary shares are entitled to one vote per share at any general meeting of the Company.

17 Dividends

The following dividends were recognised during the year:

| | 2016 €000 | 2015 €000 |
|--|--------------|--------------|
| Dividends paid of €106.94 per share (2015: €50.46 per share) | 22,982 | 10,844 |

18 Controlling parties

As at 31 December 2016 the immediate parent undertaking was INEOS Industries Limited, a company incorporated in England and Wales.

The ultimate parent company at 31 December 2016 was INEOS Limited, a company incorporated in Isle of Man.

INEOS Industries Limited is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements. Copies of the financial statements can be obtained from the Company Secretary Ineos Industries Limited, Hawkslease, Chapel Lane, Lyndhurst, Hampshire, UK, SO43 7FG.

The directors regard Mr J A Ratcliffe to be the ultimate controlling party by virtue of his majority shareholding in the ultimate parent undertaking INEOS Limited.